WINTON GROUP Ltd Reduces Stock Position in Xencor, Inc. (NASDAQ:XNCR)

WINTON GROUP Ltd trimmed its stake in shares of Xencor, Inc. (NASDAQ:XNCR) by 3.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 53,705 shares of the biopharmaceutical company’s stock after selling 2,042 shares during the period. WINTON GROUP Ltd owned approximately 0.08% of Xencor worth $1,234,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Thrivent Financial for Lutherans raised its stake in Xencor by 127.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 116,369 shares of the biopharmaceutical company’s stock valued at $2,340,000 after buying an additional 65,180 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Xencor during the third quarter valued at $362,000. Intech Investment Management LLC bought a new position in Xencor in the third quarter valued at about $368,000. Charles Schwab Investment Management Inc. boosted its position in Xencor by 7.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 626,988 shares of the biopharmaceutical company’s stock worth $12,609,000 after purchasing an additional 40,788 shares during the last quarter. Finally, FMR LLC grew its stake in shares of Xencor by 315.5% during the 3rd quarter. FMR LLC now owns 16,764 shares of the biopharmaceutical company’s stock valued at $337,000 after purchasing an additional 12,729 shares during the period.

Analysts Set New Price Targets

Several brokerages have recently weighed in on XNCR. StockNews.com cut shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. Wells Fargo & Company dropped their price target on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Finally, Piper Sandler upgraded Xencor from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $20.00 to $30.00 in a research note on Monday, December 2nd. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $34.38.

Xencor Stock Up 4.1 %

XNCR opened at $11.51 on Friday. The firm’s fifty day moving average is $15.72 and its 200 day moving average is $20.14. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. Xencor, Inc. has a fifty-two week low of $10.90 and a fifty-two week high of $27.24. The stock has a market cap of $811.02 million, a price-to-earnings ratio of -3.60 and a beta of 0.74.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.19. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The company had revenue of $52.79 million for the quarter, compared to the consensus estimate of $17.14 million. On average, sell-side analysts forecast that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.